{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:16:27Z","timestamp":1777482987668,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1136\/ard.2010.144063","type":"journal-article","created":{"date-parts":[[2011,5,4]],"date-time":"2011-05-04T02:23:05Z","timestamp":1304475785000},"page":"1264-1271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":202,"title":["Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study"],"prefix":"10.1016","volume":"70","author":[{"given":"Naomi","family":"Schlesinger","sequence":"first","affiliation":[]},{"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[]},{"given":"Hsiao-Yi","family":"Lin","sequence":"additional","affiliation":[]},{"given":"Marc","family":"De Meulemeester","sequence":"additional","affiliation":[]},{"given":"Jozef","family":"Rovensky","sequence":"additional","affiliation":[]},{"given":"Udayasankar","family":"Arulmani","sequence":"additional","affiliation":[]},{"given":"Alison","family":"Balfour","sequence":"additional","affiliation":[]},{"given":"Gerhard","family":"Krammer","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Sallstig","sequence":"additional","affiliation":[]},{"given":"Alexander","family":"So","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/ard.2010.144063_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/ajkd.2002.33911","article-title":"The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994.","volume":"40","author":"Kramer","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1136\/ard.2010.144063_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/ard.2004.024091","article-title":"Gout epidemiology: results from the UK General Practice Research Database, 1990-1999.","volume":"64","author":"Mikuls","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.144063_bib3","first-page":"759","article-title":"Diagnosis of gout.","volume":"98","author":"Schlesinger","year":"2007","journal-title":"Minerva Med"},{"issue":"15 Suppl","key":"10.1136\/ard.2010.144063_bib4","first-page":"S443","article-title":"Diagnosis of gout: clinical, laboratory, and radiologic findings.","volume":"11","author":"Schlesinger","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1136\/ard.2010.144063_bib5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","article-title":"Prevalence of contraindications and prescription of pharmacologic therapies for gout.","volume":"124","author":"Keenan","year":"2011","journal-title":"Am J Med"},{"key":"10.1136\/ard.2010.144063_bib6","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1136\/ard.2010.128454","article-title":"The pathogenesis of bone erosions in gouty arthritis.","volume":"69","author":"Schlesinger","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.144063_bib7","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.071229","article-title":"Quality of life and disability in patients with treatment-failure gout.","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.144063_bib8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/rheumatology\/kep047","article-title":"Perceptions of disease and health-related quality of life among patients with gout.","volume":"48","author":"Lee","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2010.144063_bib9","first-page":"S673","article-title":"Work productivity loss due to flares in treatment-failure gout.","volume":"58","author":"Edwards","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.144063_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3810\/pgm.2010.03.2133","article-title":"Diagnosing and treating gout: a review to aid primary care physicians.","volume":"122","author":"Schlesinger","year":"2010","journal-title":"Postgrad Med"},{"key":"10.1136\/ard.2010.144063_bib11","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/14656560902950742","article-title":"Gout\u2013what are the treatment options?","volume":"10","author":"Schlesinger","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1136\/ard.2010.144063_bib12","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.144063_bib13","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/pgmj.2004.030692","article-title":"Diagnosis and management of gout: a rational approach.","volume":"81","author":"Suresh","year":"2005","journal-title":"Postgrad Med J"},{"key":"10.1136\/ard.2010.144063_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4615-5381-6_3","article-title":"Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment.","volume":"431","author":"Yamanaka","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2010.144063_bib15","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.144063_bib16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy.","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.144063_bib17","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.144063_bib18","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.144063_bib19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.1780170517","article-title":"Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients.","volume":"17","author":"Paulus","year":"1974","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.144063_bib20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-55-2-179","article-title":"Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects.","volume":"55","author":"Yu","year":"1961","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2010.144063_bib21","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard.2010.144063_bib22","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout.","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.144063_bib23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/ar2509","article-title":"Developments in the scientific and clinical understanding of gout.","volume":"10","author":"So","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard.2010.144063_bib24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome.","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1136\/ard.2010.144063_bib25","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.4049\/jimmunol.0803007","article-title":"The mechanism of osteoclast differentiation induced by IL-1.","volume":"183","author":"Kim","year":"2009","journal-title":"J Immunol"},{"key":"10.1136\/ard.2010.144063_bib26","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/art.23653","article-title":"Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption.","volume":"58","author":"Tunyogi-Csapo","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.144063_bib27","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/ar2438","article-title":"The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis.","volume":"10","author":"Alten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard.2010.144063_bib28","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.144063_bib29","first-page":"264","article-title":"Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout.","volume":"18","author":"Wallace","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.144063_bib30","article-title":"Placebo-controlled study of rilonacept for gout flare prophylaxis during initiation of urate-lowering therapy.","author":"Schumacher","year":"2009","journal-title":"ACR"},{"key":"10.1136\/ard.2010.144063_bib31","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1002\/art.27635","article-title":"Interleukin-1 antagonism in acute gout: is targeting a single cytokine the answer?","volume":"62","author":"Neogi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.144063_bib32","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome.","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.144063_bib33","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2010.144063_bib34","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3899\/jrheum.090370","article-title":"Outcome domains for studies of acute and chronic gout.","volume":"36","author":"Schumacher","year":"2009","journal-title":"J Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724100519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724100519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2010.144063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T09:19:21Z","timestamp":1736068761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724100519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0003496724100519"],"URL":"https:\/\/doi.org\/10.1136\/ard.2010.144063","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2010.144063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc. For permission to use (where not already granted under a licence) please go to http:\/\/group.bmj.com\/group\/rights-licensing\/permissions. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}